Financhill
Sell
19

SOLTF Quote, Financials, Valuation and Earnings

Last price:
$6.16
Seasonality move :
12.54%
Day range:
$6.16 - $6.16
52-week range:
$6.16 - $13.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.79x
P/B ratio:
1.17x
Volume:
--
Avg. volume:
137
1-year change:
-37.04%
Market cap:
$553.6M
Revenue:
$91M
EPS (TTM):
-$0.27

Analysts' Opinion

  • Consensus Rating
    Nxera Pharma has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Downside
    According to analysts' consensus price target of --, Nxera Pharma has an estimated downside of -- from its current price of $6.16.
  • Price Target Upside
    According to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $6.16.

Fair Value

  • According to the consensus of 0 analysts, Nxera Pharma has -- downside to fair value with a price target of -- per share.

SOLTF vs. S&P 500

  • Over the past 5 trading days, Nxera Pharma has underperformed the S&P 500 by -10.39% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Nxera Pharma does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Nxera Pharma has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Nxera Pharma reported revenues of $62.4M.

Earnings Growth

  • Nxera Pharma has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Nxera Pharma reported earnings per share of $0.09.
Enterprise value:
665.8M
EV / Invested capital:
0.72x
Price / LTM sales:
2.79x
EV / EBIT:
--
EV / Revenue:
3.42x
PEG ratio (5yr expected):
--
EV / Free cash flow:
66.55x
Price / Operating cash flow:
54.27x
Enterprise value / EBITDA:
96.78x
Gross Profit (TTM):
$146.8M
Return On Assets:
-2.38%
Net Income Margin (TTM):
-12.61%
Return On Equity:
-5.58%
Return On Invested Capital:
-2.75%
Operating Margin:
8.72%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $189M $88.1M $194.8M $23M $62.4M
Gross Profit $180.5M $77.3M $146.8M $15.2M $48.9M
Operating Income $62.1M -$28.7M -$29.4M -$26.5M $5.4M
EBITDA $55.4M -$4.7M $6.9M -$18.4M $13.8M
Diluted EPS -$0.02 -$0.29 -$0.27 -$0.41 $0.09
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $377.3M $462.9M $440.2M $390.3M $419.1M
Total Assets $693.8M $794.6M $658.8M $1B $1.1B
Current Liabilities $21.2M $33.7M $21.2M $117.6M $104.7M
Total Liabilities $237.4M $314.3M $273.2M $612.4M $592.2M
Total Equity $456.4M $480.4M $385.6M $387.9M $474.5M
Total Debt $139.3M $243.9M $192.7M $457.2M $454.4M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $126M $10.4M $15.1M -$9.1M $12.2M
Cash From Investing -$1.4M -$427.3M -$17.7M -$423M -$1.6M
Cash From Financing -$35.3M $271.6M $35.5M $274.9M -$12.4M
Free Cash Flow $123.7M $6M $10M -$11.1M $10.3M
SOLTF
Sector
Market Cap
$553.6M
$46.5M
Price % of 52-Week High
45.85%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-37.04%
-31.38%
Beta (5-Year)
0.337
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $6.49
200-day SMA
Sell
Level $9.12
Bollinger Bands (100)
Sell
Level 7.28 - 9.42
Chaikin Money Flow
Buy
Level 11.1K
20-day SMA
Sell
Level $7.04
Relative Strength Index (RSI14)
Sell
Level 9.27
ADX Line
Sell
Level 49.68
Williams %R
Buy
Level -100
50-day SMA
Sell
Level $7.46
MACD (12, 26)
Sell
Level -0.43
25-day Aroon Oscillator
Sell
Level -84
On Balance Volume
Sell
Level -39.4K

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.9687)
Sell
CA Score (Annual)
Level (-0.7596)
Sell
Beneish M-Score (Annual)
Level (-1.2854)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.411)
Sell
Piotroski F Score (Annual)
Level (2)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Stock Forecast FAQ

In the current month, SOLTF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SOLTF average analyst price target in the past 3 months is --.

  • Where Will Nxera Pharma Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Nxera Pharma share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Nxera Pharma?

    Analysts are divided on their view about Nxera Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nxera Pharma is a Sell and believe this share price will rise from its current level to --.

  • What Is Nxera Pharma's Price Target?

    The price target for Nxera Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is SOLTF A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Nxera Pharma is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of SOLTF?

    You can purchase shares of Nxera Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nxera Pharma shares.

  • What Is The Nxera Pharma Share Price Today?

    Nxera Pharma was last trading at $6.16 per share. This represents the most recent stock quote for Nxera Pharma. Yesterday, Nxera Pharma closed at $6.16 per share.

  • How To Buy Nxera Pharma Stock Online?

    In order to purchase Nxera Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is AMD Stock an All-Time Buy?
Is AMD Stock an All-Time Buy?

Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…

How High Will Airbnb Stock Go?
How High Will Airbnb Stock Go?

Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 43x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
57
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
64
ARQQ alert for Dec 27

Arqit Quantum [ARQQ] is down 7.05% over the past day.

Buy
64
QMCO alert for Dec 27

Quantum [QMCO] is up 2.86% over the past day.

Buy
65
ALGS alert for Dec 27

Aligos Therapeutics [ALGS] is down 3.69% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock